MedTrace Logo

Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

NCT02631096 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-06-29

No results posted yet for this study

Summary

The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

ARB-001467

An IV infusion of ARB-001467

OTHER

Placebo

An IV infusion of placebo

Sponsors & Collaborators

  • Arbutus Biopharma Corporation

    lead INDUSTRY

Principal Investigators

  • Patricia Mendez, MD, PhD · Arbutus Biopharma Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-05-18
Completion
2018-05-18

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631096 on ClinicalTrials.gov